Treatments
TL;DR: 12 FDA-approved drugs have labels that mention stomach cancer in their indications. Grouped below by mechanism of action. This list gives you the vocabulary — your oncologist chooses a regimen based on your specific subtype, stage, biomarkers, and prior therapies.
Source: OpenFDA drug label API · last checked
Cost transparency
Drugs below have published Medicare Part B or Part D spending figures — what the federal government actually paid per beneficiary in 2023.
Immunotherapy (PD-1 inhibitor)
Immunotherapy (PD-1 inhibitor)
Targeted antibody (HER2)
Antibody-drug conjugate (HER2)
Figures are average Medicare spending per beneficiary. Out-of-pocket varies by insurance and manufacturer assistance. See all drug costs →
Drugs that activate or modify the immune system to attack cancer cells. Checkpoint inhibitors (targeting PD-1, PD-L1, CTLA-4) are the most common.
Programmed Death Receptor-1 Blocking Antibody [EPC] · Programmed Death Receptor-1-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agen…
Programmed Death Receptor-1 Blocking Antibody [EPC] · Endoglycosidase [EPC]
From the FDA label: 1 INDICATIONS AND USAGE OPDIVO QVANTIG is a combination of nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of: Renal Cell Carcinoma (RCC) • adult patients…
Programmed Death Receptor-1 Blocking Antibody [EPC] · Programmed Death Receptor-1-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric…
Endoglycosidase [EPC] · Programmed Death Receptor-1 Blocking Antibody [EPC]
From the FDA label: 1 INDICATIONS AND USAGE KEYTRUDA QLEX is a combination of pembrolizumab, a programmed death receptor-1 (PD-1)-blocking antibody, and berahyaluronidase alfa, an endoglycosidase, indicated: Melanoma for the treatment of adult patients with un…
Programmed Death Receptor-1 Blocking Antibody [EPC] · Programmed Death Receptor-1-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE TEVIMBRA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for: Esophageal Cancer in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or met…
Monoclonal antibodies and antibody-drug conjugates (ADCs) that bind specific proteins on cancer cells.
From the FDA label: 1 INDICATIONS AND USAGE ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated: HER2-Positive Metastatic Breast Cancer in combination with pertuzumab as first-line treatment of adult patients with unresectable o…
HER2/neu Receptor Antagonist [EPC] · HER2/Neu/cerbB2 Antagonists [MoA]
From the FDA label: 1 INDICATIONS AND USAGE Herceptin is a HER2/neu receptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer. ( 1.1 , 1.2 ) The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junct…
HER2/neu Receptor Antagonist [EPC] · HER2/Neu/cerbB2 Antagonists [MoA]
From the FDA label: 1 INDICATIONS AND USAGE KANJINTI is a HER2/neu receptor antagonist indicated in adults for: the treatment of HER2-overexpressing breast cancer. ( 1.1 , 1.2 ) the treatment of HER2-overexpressing metastatic gastric or gastroesophageal juncti…
HER2/neu Receptor Antagonist [EPC] · HER2/Neu/cerbB2 Antagonists [MoA]
From the FDA label: 1 INDICATIONS AND USAGE Ogivri is a HER2/neu receptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer. ( 1.1 , 1.2 ) The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction…
HER2/neu Receptor Antagonist [EPC] · HER2/Neu/cerbB2 Antagonists [MoA]
From the FDA label: 1 INDICATIONS AND USAGE TRAZIMERA is a HER2/neu receptor antagonist indicated in adults for: • The treatment of HER2-overexpressing breast cancer. ( 1.1 , 1.2 ) • The treatment of HER2-overexpressing metastatic gastric or gastroesophageal j…
Small-molecule drugs taken by mouth that block specific molecular pathways driving cancer growth (kinases, PARP, CDK4/6, etc.).
Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] · VEGFR2 Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE CYRAMZA ® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or ga…
Drugs whose pharmacologic class was not automatically classified into the groups above. Check the FDA label for mechanism details.
Nucleoside Analog Antiviral [EPC] · Nucleoside Metabolic Inhibitor [EPC]
From the FDA label: 1 INDICATIONS AND USAGE LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of adult patients with: metastatic colorectal cancer as a si…
Disease foundations below have active funds covering stomach cancer medications. Manufacturer patient-assistance programs are listed on each drug's cost page.
copay, premium, and deductible assistance for insured patients; fund availability varies by disease
https://www.healthwellfoundation.org/disease-funds/Funds open and close based on availability; check disease-funds page for current status
Trials test new therapies before they are FDA-approved. Often a way to access tomorrow's drugs today.
Back to Stomach Cancer hub →Stats, second opinions, NCI cancer centers, oncologists.
Understand biomarkers →Most targeted therapies require biomarker testing. Here's what you need to know.
Read your pathology report →Which drugs apply to you depends on what's in your pathology.